

Piyush K Agarwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5287761/publications.pdf>

Version: 2024-02-01

90
papers

3,289
citations

136950

32
h-index

149698

56
g-index

92
all docs

92
docs citations

92
times ranked

4242
citing authors

#	ARTICLE	IF	CITATIONS
1	Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. PLoS ONE, 2021, 16, e0241766.	2.5	4
2	Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. American Journal of Roentgenology, 2020, 214, 105-113.	2.2	17
3	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. Journal of Clinical Oncology, 2020, 38, 3672-3684.	1.6	78
4	Multiresolution Application of Artificial Intelligence in Digital Pathology for Prediction of Positive Lymph Nodes From Primary Tumors in Bladder Cancer. JCO Clinical Cancer Informatics, 2020, 4, 367-382.	2.1	42
5	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World Journal of Urology, 2019, 37, 51-60.	2.2	31
6	Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. Journal of Immunology, 2019, 202, 3458-3467.	0.8	36
7	Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT). Scientific Reports, 2019, 9, 2084.	3.3	57
8	Clinical Trials Corner. Bladder Cancer, 2019, 5, 83-84.	0.4	0
9	Clinical Trials Corner. Bladder Cancer, 2019, 5, 185-187.	0.4	0
10	Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc. Scientific Reports, 2019, 9, 18409.	3.3	10
11	Clinical Trials Corner. Bladder Cancer, 2018, 4, 133-136.	0.4	0
12	Lymph node dissection during radical cystectomy following prior radiation therapy: results from the SEER database. International Urology and Nephrology, 2018, 50, 257-262.	1.4	3
13	Editorial Comment. Journal of Urology, 2018, 199, 414-415.	0.4	0
14	Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M. Cellular and Molecular Life Sciences, 2018, 75, 939-963.	5.4	36
15	Lymph node imaging in testicular cancer. Translational Andrology and Urology, 2018, 7, 864-874.	1.4	30
16	Clinical Trials Corner. Bladder Cancer, 2018, 4, 447-449.	0.4	0
17	Clinical Trials Corner. Bladder Cancer, 2018, 4, 243-244.	0.4	0
18	Photodynamic Therapy in the Treatment of Bladder Cancer: Past Challenges and Current Innovations. European Urology Focus, 2018, 4, 509-511.	3.1	62

#	ARTICLE	IF	CITATIONS
19	Incidental bladder cancers found on multiparametric MRI of the prostate gland: a single center experience. <i>Diagnostic and Interventional Radiology</i> , 2018, 24, 316-320.	1.5	12
20	Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma. <i>Clinical Epigenetics</i> , 2018, 10, 19.	4.1	22
21	Bilateral Ureteroenteric Strictures: A Case of the "Reverse 7". <i>Urology</i> , 2018, 118, e3-e4.	1.0	4
22	Clinical Trials Corner. <i>Bladder Cancer</i> , 2018, 4, 347-350.	0.4	0
23	New therapies in nonmuscle invasive bladder cancer treatment. <i>Indian Journal of Urology</i> , 2018, 34, 11.	0.6	35
24	Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2201-2214.	4.1	59
25	Advances in medical imaging for the diagnosis and management of common genitourinary cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 473-491.	1.6	44
26	Genitourinary paraganglioma: Demographic, pathologic, and clinical characteristics in the surveillance, epidemiology, and end results database (2000-2012). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 457.e9-457.e14.	1.6	25
27	Lyso-thermosensitive liposomal doxorubicin for treatment of bladder cancer. <i>International Journal of Hyperthermia</i> , 2017, 33, 1-8.	2.5	20
28	Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics. <i>Scientific Reports</i> , 2017, 7, 201.	3.3	46
29	Chronic Colovesical Fistula Leading to Chronic Urinary Tract Infection Resulting in End-Stage Renal Disease in a Chronic Granulomatous Disease Patient. <i>Urology Case Reports</i> , 2017, 11, 37-38.	0.3	3
30	Case Presentation: Lung Consolidation as Sequelae of BCG Sepsis After Combined Intravesical and Intraurethral BCG. <i>Urology Case Reports</i> , 2017, 13, 152-153.	0.3	5
31	Current clinical trials in non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 516-527.	1.6	29
32	The Sunshine Act and oncology: Lessons learned from urology. <i>Seminars in Oncology</i> , 2017, 44, 265-266.	2.2	0
33	Clinical Trials Corner. <i>Bladder Cancer</i> , 2017, 3, 229-230.	0.4	0
34	Clinical Trials Corner. <i>Bladder Cancer</i> , 2017, 3, 315-317.	0.4	0
35	Clinical Trials Corner. <i>Bladder Cancer</i> , 2017, 3, 141-142.	0.4	0
36	Clinical Trials Corner. <i>Bladder Cancer</i> , 2016, 2, 469-471.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Nonmuscle invasive bladder cancer: a primer on immunotherapy. <i>Cancer Biology and Medicine</i> , 2016, 13, 194-205.	3.0	17
38	Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach. <i>International Journal of Oncology</i> , 2016, 48, 2591-2607.	3.3	26
39	Novel immunotherapeutic approaches to the treatment of urothelial carcinoma. <i>Therapeutic Advances in Urology</i> , 2016, 8, 203-214.	2.0	9
40	A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4534-4534.	1.6	8
41	Structured Reporting of RARP Complications: Are We Making Measurable Progress?. , 2016, , 227-246.		0
42	Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma. <i>Current Opinion in Urology</i> , 2015, 25, 468-475.	1.8	2
43	Evolving Immunotherapy Strategies in Urothelial Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e284-e290.	3.8	3
44	Trimodality Therapy in Bladder Cancer. <i>Urologic Clinics of North America</i> , 2015, 42, 169-180.	1.8	36
45	Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 167.e13-167.e20.	1.6	24
46	Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder. <i>Cancers</i> , 2014, 6, 2313-2329.	3.7	14
47	New facial papules in a 66-year-old woman with bladder cancer. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1250-1255.	1.2	3
48	Clinical significance of ureteric â€˜skip lesionsâ€™™ at the time of radical cystectomy: the <scp>M</scp>.<scp>D</scp>. <scp>A</scp>nderson experience and literature review. <i>BJU International</i> , 2014, 113, E28-33.	2.5	16
49	Targeted therapies in urothelial carcinoma. <i>Current Opinion in Oncology</i> , 2014, 26, 305-320.	2.4	40
50	Analysis of Intracorporeal Compared with Extracorporeal Urinary Diversion After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>European Urology</i> , 2014, 65, 340-347.	1.9	242
51	Multimodal management of muscle-invasive bladder cancer. <i>Current Problems in Cancer</i> , 2014, 38, 80-108.	2.0	76
52	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046).. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 637-644.	1.6	46
53	The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 29.e13-29.e20.	1.6	34
54	Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review). <i>Molecular and Clinical Oncology</i> , 2014, 2, 656-660.	1.0	25

#	ARTICLE	IF	CITATIONS
55	A randomized, prospective, phase II study to determine the efficacy of BCG given in combination with panvac versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least one induction course of BCG.. Journal of Clinical Oncology, 2014, 32, TPS4590-TPS4590.	1.6	6
56	Reply from Authors re: Manfred P. Wirth, Johannes Huber. What Really Matters Is Rarely Measured: Outcome of Routine Care and Patient-reported Outcomes. Eur Urol 2013;64:58-61. European Urology, 2013, 64, 60-61.	1.9	0
57	Effect of metabolic syndrome on pathologic features of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1054-1059.	1.6	44
58	Complications After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. European Urology, 2013, 64, 52-57.	1.9	189
59	Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (<scp>IRCC</scp>). BJU International, 2013, 111, 1075-1080.	2.5	49
60	Low Grade Micropapillary Urothelial Carcinoma, Does It Exist? - Analysis of Management and Outcomes from the Surveillance, Epidemiology and End Results (SEER) Database. Journal of Cancer, 2013, 4, 336-342.	2.5	26
61	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. Journal of Clinical Oncology, 2013, 31, 314-314.	1.6	6
62	Perioperative management of radical cystectomy patients: A questionnaire survey of the American Urological Association members.. Journal of Clinical Oncology, 2013, 31, 316-316.	1.6	3
63	Low-grade micropapillary urothelial carcinoma: Does it exist? A SEER analysis of management and outcomes.. Journal of Clinical Oncology, 2013, 31, 315-315.	1.6	0
64	Paragangliomas of the urinary bladder: Experience at the National Cancer Institute.. Journal of Clinical Oncology, 2013, 31, 307-307.	1.6	1
65	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. Journal of Clinical Oncology, 2013, 31, 4543-4543.	1.6	1
66	Disparities in access to care at high-volume institutions for urologic oncologic procedures. Cancer, 2012, 118, 4421-4426.	4.1	65
67	Leapfrog volume thresholds and perioperative complications after radical prostatectomy. Cancer, 2012, 118, 4991-4998.	4.1	17
68	Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 372-377.	1.6	6
69	Safety Profile of Robot-Assisted Radical Prostatectomy: A Standardized Report of Complications in 3317 Patients. European Urology, 2011, 59, 684-698.	1.9	114
70	Neoadjuvant hormonal therapy does not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer. World Journal of Urology, 2011, 29, 689-694.	2.2	6
71	Development of the Vattikuti Institute Prostatectomy: Historical Perspective and Technical Nuances. , 2011, , 219-241.		0
72	Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. BJU International, 2010, 106, 1799-1804.	2.5	35

#	ARTICLE	IF	CITATIONS
73	Early oncological outcomes of robotâ€assisted radical prostatectomy for highâ€grade prostate cancer. BJU International, 2010, 106, 1739-1745.	2.5	18
74	Men Presenting for Radical Prostatectomy on Preoperative Statin Therapy Have Reduced Serum Prostate Specific Antigen. Journal of Urology, 2010, 183, 118-125.	0.4	42
75	Ultrasonographic Evaluation of Renal Infections. Ultrasound Clinics, 2010, 5, 355-366.	0.2	4
76	Vattikuti Institute Prostatectomy: Technical Modifications in 2009. European Urology, 2009, 56, 89-96.	1.9	138
77	Outcome of Patients With Bladder Cancer With pN+ Disease After Preoperative Chemotherapy and Radical Cystectomy. Urology, 2009, 73, 147-152.	1.0	63
78	Treatment failure after primary and salvage therapy for prostate cancer. Cancer, 2008, 112, 307-314.	4.1	314
79	Considerations on the use of diagnostic markers in management of patients with bladder cancer. World Journal of Urology, 2008, 26, 39-44.	2.2	21
80	Lymph Node Density Is Superior to TNM Nodal Status in Predicting Disease-Specific Survival After Radical Cystectomy for Bladder Cancer: Analysis of Pooled Data From MDACC and MSKCC. Journal of Clinical Oncology, 2008, 26, 121-126.	1.6	161
81	Emerging drugs for targeted therapy of bladder cancer. Expert Opinion on Emerging Drugs, 2007, 12, 435-448.	2.4	7
82	Targeted therapies in bladder cancerâ€an update. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 433-438.	1.6	77
83	Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer, 2007, 109, 198-204.	4.1	98
84	Ultrasonographic Evaluation of Renal Infections. Ultrasound Clinics, 2006, 1, 1-13.	0.2	2
85	Retractile Testisâ€Is it Really a Normal Variant?. Journal of Urology, 2006, 175, 1496-1499.	0.4	114
86	Testicular and Paratesticular Neoplasms in Prepubertal Males. Journal of Urology, 2006, 176, 875-881.	0.4	80
87	Testicular neoplasms in the prepubertal male. The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2006, 3, 131-138.	0.2	4
88	Prepubertal male and testicular neoplasms: Diagnosis and treatment. Drugs of Today, 2006, 42, 127.	1.1	1
89	TESTOSTERONE REPLACEMENT THERAPY AFTER PRIMARY TREATMENT FOR PROSTATE CANCER. Journal of Urology, 2005, 173, 533-536.	0.4	182
90	SURVIVAL OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN ERA. Journal of Urology, 2004, 171, 1525-1528.	0.4	64